Fig. 1

Azacytidine mitigates scl-cGVHD. Balb/cJ mice were injected i.v. with 10.10⁶ bone marrow cells and 70.10⁶ splenocytes from B10.D2 donor mice (or from Balb/cJ mice in case of syngeneic transplantation) after lethal irradiation. Mice were then given (or not) azacytidine (AZA) administered subcutaneously every 48 h from day +10 to day +30. Animals were individually scored three times/week and animals reaching a score of 8/10 were sacrificed (evolutions of the number of animals along the course of each experiment are shown under each graph). a Pooled GVHD scoring of two independent groups (two distinct experiments) of mice given or not AZA (0.5 or 2 mg/kg) showing lower GVHD scores in AZA-treated mice. Two out of 15 control mice died during the experiments due to achievement of the critical score of 8/10 and three others because of weight loss >20 %. Concerning mice receiving AZA 0,5 mg/kg, three out of 14 mice were sacrificed during the experiment because a weight loss >20 % and 1 due to achievement of the critical score. For mice treated with AZA 2 mg/kg, two mice were sacrificed because of a weight loss >20 % and two did not survive the anesthesia administered for skin biopsy performed during the experiment (day +29). b GVHD scoring of a third cohort of mice given or not AZA (2 mg/kg only) confirming lower GVHD scores in treated mice. Three out of eight control mice were sacrificed because they achieved the critical score of 8/10, while all AZA mice survived without achieving the critical GVHD score. Results are expressed as mean with SEM. *P < 0.05; **P < 0.01; ***P < 0.001